Odaily Planet Daily reports: Nasdaq-listed company Canton Strategic Holdings has announced the completion of the sale of its biotechnology R&D division, Gravitas Life Sciences. The buyer is Gravitas Collective Corp., and the transaction was unanimously approved by the company’s board of directors, with closing officially completed on July 17, 2026.
This asset divestment is a key strategic move for the company, which will subsequently focus on the Canton Network ecosystem and transform into a digital services provider for financial markets, with an emphasis on advancing asset tokenization and the implementation of financial digitization, while continuously enhancing its compliant financial infrastructure services. (PRNewswire)